Recent strategies for the treatment of multi-drug resistance in cancer cells

Bibliography

• Taxane Anticancer Agents: Basic Science and Current Status. Georg GI, Chen TT, Ojima I, Vyas DM (Eds.), Ameri-can Chemical Society, Washington, DC (1995).
   Google Scholar
• Taxol: Science and Applications. Suffness M (Ed.), CRC Press, New York (1995).
   Google Scholar
• FORD JM: Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitizers. Eur. J. Cancer (1996) 32A:991–1001.
   PubMed Web of Science ®Google Scholar
• ••Recent review on the different classes of MDR modulatorsand their mechanisms of action.
   Google Scholar
• SIMON SM, SCHINDLER M: Cell biological mechanisms of multidrug resistance in tumors. Proc. Natl. Acad. ScL USA (1994) 91:3497–3504.
   PubMed Web of Science ®Google Scholar
• ••Detailed discussion on the molecular mechanisms of MDR.
   Google Scholar
• ROBERT J: Multidrug resistance reversal agents. Drugs Future (1997) 22:149–158.
   Google Scholar
• ••Another recent review on MDR modulators with emphasison the biochemistry and the status of clinical trials.
   Google Scholar
• TSURUO T, IIDA H, TSUKAGOSHI S, SAKURAI Y: Over-coming of vincristine resistance in P388 leukaemia in vivo and in vitro through enhanced cytotoxicity of yin-cristine and vinblastine by verapamil. Cancer Res. (1981) 41:1967–1972.
   PubMed Web of Science ®Google Scholar
• FORD JM, BRUGGEMANN EP, PASTAN I, GOTTESMAN MM, HAIT WN: Cellular and biochemical characteriza-tion of thioxanthenes for reversal of multidrug resis-tance in human and murine cell lines. Cancer Res. (1990) 50:1748–1756.
   PubMedGoogle Scholar
• TWENTYMAN PR: Modification of cytotoxic drug resis-tance by non-immuno-suppressive cyclosporins. Br. J. Cancer (1988) 57:254–258.
   PubMed Web of Science ®Google Scholar
• JACHEZ B, NORDMANN R, LOOR F: Restoration of taxol sensitivity of multidrug resistant cells by the cyclo-sporine SDZ PSC833 and the cyclopeptolide SDZ 280-446.j Natl. Cancer Inst. (1993) 85:478–483.
   PubMed Web of Science ®Google Scholar
• WANG L, YANG CPH, HORWITZ SB, TRAIL PA, CASAZZA AM: Reversal of the human and murine multidrug re-sistance phenotype with megestrol acetate. Cancer Chemother. Pharmacol (1994) 34:96–102.
   PubMedGoogle Scholar
• CHATTERJEE M, HARRIS AL: Reversal of acquired resis-tance to adriamycin in CHO cells by tamoxifen and 4-hydroxy tamoxifen: role of drug interaction with al-pha 1 acid glycoprotein. Br. J. Cancer (1990) 62:712–717.
   PubMed Web of Science ®Google Scholar
• CHAUFFERT B, MARTIN M, HAMMANN A, MICHEL MF, MARTIN F: Amiodarone-induced enhancement of doxorubicin and 4'-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo. Cancer Res. (1986) 46:825–830.
   PubMedGoogle Scholar
• NAKANISHI 0, TSURUO T: Multidrug resistance-reversing agents for potential clinical use. In: Multi-drug Resistance in Cancer Cells. Gupta S, Tsuruo T (Eds.), John Wiley & Sons Ltd. (1996):375–384.
   Google Scholar
• HYAFIL F, VERGELY C, DU VIGNAUD P, GRAND-PERRET T: In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. (1993) 53:4595–4602.
   PubMed Web of Science ®Google Scholar
• JULIA AM, ROCHE H, BERLION M et al: Multidrug resis-tance circumvention by a new triazinoamino-piperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil. Br. J. Cancer (1994) 69:868–874.
   PubMed Web of Science ®Google Scholar
• TURNER RN, CURTIN NJ: Dipyridamole increases VP16growth inhibition, accumulation and retention in pa-rental and multidrug-resistant CHO cells. Br. J. Cancer (1996) 73:856–860.
   PubMed Web of Science ®Google Scholar
• LIU Z, LHEUREUX F, POULIOT JF et al: BIB22 BS, potentmultidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells. Mol Pharmacol. (1996) 50:482–492.
   PubMedGoogle Scholar
• ECKER G, CHIBA P: Recent developments in overcom-ing tumour cell multidrug resistance. Exp. Opin. Ther. Patents (1997) 7:589–599.
   Web of Science ®Google Scholar
• •The article covers the patent literature of MDR modulators for the years 1995 and 1996.
   Google Scholar
• BREIER A, BARANCIK M, STEFANKOVA Z, UHRIK B, TRIBULOVA N: Effect of pentoxifylline on P-glycoprotein mediated vincristine resistance of L1210 mouse leukemic cell line. Neoplasma (1994) 41:297–303.
   PubMedGoogle Scholar
• DANTZIG AH, SHEPARD RL, CAO J et al.: Reversal of P-glycoprotein-mediated multidrug resistance by a po-tent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. (1996) 56:4171–4179.
   PubMed Web of Science ®Google Scholar
• ANDRUS MB, LEPORE SD: Synthesis of stipiamide and anew multidrug resistance reversal agent, 6,7-dehydrostipiamide. J. Am. Chem. Soc. (1997) 119:2327–2328.
   Google Scholar
• GERMANN UA, SHLYAKHTER D, MASON VS eta].: Cellularand biochemical characterization of VX-710 as a che-mosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. AntiCancer Drugs (1997) 8:125–140.
   Google Scholar
• FORD JM, PROZIALECK WC, HAIT WN: Structural fea-tures determining activity of phenothiazines and re-lated drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol (1989) 35:105–115.
   PubMed Web of Science ®Google Scholar
• CHIBA P, BURGHOFER S, RICHTER E et al.: Synthesis,pharmacologic activity, and structure-activity rela-tionships of a series of propafenone-related modula-tors of multidrug resistance. J. Med. Chem. (1995) 38:2789–2793.
   PubMedGoogle Scholar
• ECKER G, CHIBA P, HITZLER M et al.: Structure-activityrelationship studies on benzofuran analogs of propafenone-type modulators of tumor cell multidrug resistance. J. Med. Chem. (1996) 39:4767–4774.
   PubMed Web of Science ®Google Scholar
• OJIMA I, BOUNAUD PY, TAKEUCHI C, PERA P, BERNACKIRJ: New taxanes as highly efficient reversal agents for multidrug resistance in cancer cells. Bioorg. Med. Chem. Lett. (1998) 8:189–194.
   PubMedGoogle Scholar
• STEIN W: Saturation reversal of the multidrug pumpusing many reversers in low-dose combinations. Anti-cancer drugs (1995) 6:727–35.
   PubMedGoogle Scholar